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Background: Bacterial lipoproteins often play important roles in pathogenesis and can stimulate protective
immune responses. Such lipoproteins are viable vaccine candidates. Haemophilus ducreyi, which causes the sexually
transmitted disease chancroid, expresses a number of lipoproteins during human infection. One such lipoprotein,
OmpP4, is homologous to the outer membrane lipoprotein e (P4) of H. influenzae. In H. influenzae, e (P4) stimulates
production of bactericidal and protective antibodies and contributes to pathogenesis by facilitating acquisition of
the essential nutrients heme and nicotinamide adenine dinucleotide (NAD). Here, we tested the hypothesis that,
like its homolog, H. ducreyi OmpP4 contributes to virulence and stimulates production of bactericidal antibodies.
Results: We determined that OmpP4 is broadly conserved among clinical isolates of H. ducreyi. We next constructed
and characterized an isogenic ompP4 mutant, designated 35000HPompP4, in H. ducreyi strain 35000HP. To test
whether OmpP4 was necessary for virulence in humans, eight healthy adults were experimentally infected. Each
subject was inoculated with a fixed dose of 35000HP on one arm and three doses of 35000HPompP4 on the other
arm. The overall parent and mutant pustule formation rates were 52.4% and 47.6%, respectively (P = 0.74). These
results indicate that expression of OmpP4 in not necessary for H. ducreyi to initiate disease or progress to pustule
formation in humans. Hyperimmune mouse serum raised against purified, recombinant OmpP4 did not promote
bactericidal killing of 35000HP or phagocytosis by J774A.1 mouse macrophages in serum bactericidal and
phagocytosis assays, respectively.
Conclusions: Our data suggest that, unlike e (P4), H. ducreyi OmpP4 is not a suitable vaccine candidate. OmpP4
may be dispensable for virulence because of redundant mechanisms in H. ducreyi for heme acquisition and NAD
utilization.
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Bacterial genomes usually contain a significant portion
of open reading frames (ORFs) that encode lipoproteins.
For example, the genome of Neisseria meningitidis group
B strain MC58 has 70 ORFs that encode surface-exposed
or exported putative lipoproteins [1]. Approximately 8% of
the ORFs of Borrelia burgdorferi encode putative lipopro-
teins [2]. The presence of numerous lipoproteins in bacter-
ial genomes suggests their importance for bacterial survival
and pathogenesis. Lipoproteins have been demonstrated to* Correspondence: dmjanowi@iu.edu
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unless otherwise stated.have roles in preserving membrane structure, function-
ing as enzymes, and serving as transporters or toxins.
Lipoproteins also serve as immunogens; for example,
the lipoprotein outer surface protein A (OspA), which
plays important roles in B. burgdorferi’s biology, was
used to develop an OspA-based vaccine [3,4].
Haemophilus ducreyi, the etiologic agent of the sexu-
ally transmitted genital ulcer disease chancroid, has the
capacity to express 67 putative lipoproteins (GenBank
accession number AE017143), only four of which have
been well characterized: the peptidoglycan associated
lipoprotein (PAL), the fibrinogen binding protein (FgbA),
the ducreyi lectin A (DltA), and H. ducreyi lipoproteinal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and contains a surface-exposed epitope defined by the
monoclonal antibody 3B9 [8]. An isogenic PAL mutant is
unable to cause pustules in the human infection model
[9]. FgbA and DltA also contribute to H. ducreyi virulence
in humans [5,10]. The roles of other lipoproteins in H.
ducreyi pathogenesis have not yet been delineated.
In order to better understand the bacterial factors that
contribute to the pathogenesis of H. ducreyi, an experi-
mental human model of infection was developed [11,12].
In this model, adult volunteers are inoculated with H.
ducreyi strain 35000HP, or its isogenic derivatives, on
the skin overlying the upper deltoid. Within 24 h of in-
oculation, volunteers develop papules that either resolve
or progress into pustules over the ensuing 2 weeks. Ex-
perimental infection mimics natural infection both clin-
ically and histologically and has allowed identification of
H. ducreyi genes that are expressed in vivo [13]. One of
the genes identified as being expressed in multiple volun-
teers was HD1170. HD1170 encodes a putative lipopro-
tein, designated outer membrane protein P4 (OmpP4).
OmpP4 is a homolog of the outer membrane lipopro-
tein e (P4) of H. influenzae. e (P4) is broadly conserved
among typeable and nontypeable H. influenzae (NTHI)
strains and is expressed as an abundant, immunodomi-
nant 28 kDa lipoprotein in outer membrane protein
(OMP) fractions [14]. e (P4) was shown to play a role in
virulence in an infant rat model of infection with H.
influenzae type b [15]. Mechanistically, e (P4) is a phos-
phomonoesterase that facilitates the transport of two es-
sential nutrients, heme and nicotinamide nucleotides,
across the outer membrane of NTHI [16,17]. Monoclo-
nal anti-e (P4) antibodies are highly reactive with a sur-
face exposed epitope of e (P4), and anti-e (P4) serum is
bactericidal against NTHI strains [14,18]. Immunization
with e (P4) afforded protection against colonization in a
mouse model of NTHI infection [19]. Thus, e (P4) is
being actively investigated as a vaccine candidate against
NTHI [18-20].
The predicted H. ducreyi OmpP4 shares 61% identity
with e (P4), including conservation of the functional
motifs required for enzymatic activity and for heme bind-
ing in e (P4) [21]. Because of its significant homology
with e (P4) and its in vivo expression, we hypothesized
that H. ducreyi OmpP4 may play an important role
during human infection. Here, we found that ompP4 is
conserved among clinical isolates of H. ducreyi. To in-
vestigate its role in virulence and its utility as a vaccine
candidate for H. ducreyi, we constructed and tested an
isogenic ompP4 mutant in H. ducreyi 35000HP for
virulence in human volunteers. We also tested whether
mouse serum elicited against H. ducreyi OmpP4 pro-
moted complement-mediated bactericidal activity or
phagocytic uptake.Results
Identification of the ompP4 gene
Analysis of the 35000HP genome identified an 831 bp
open reading frame (ORF) that encoded an OmpP4
homologue. Sequence analysis of ompP4 demonstrated
an N-terminal signal II peptide and a consensus lipida-
tion sequence, N-VLSGC-C (Figure 1). Based on sorting
signals described for Escherichia coli, the presence of a
tyrosine at position 2 suggests that OmpP4 sorts to the
outer membrane [22,23]. The ompP4 ORF lies within a
putative operon (Figure 1). PCR amplification of the
ORF of ompP4 demonstrated that the gene was con-
served in size and location among 10 different strains of
H. ducreyi (Figure 1). Amplicons from two class I and
two class II strains were sequenced and the deduced
OmpP4 sequences compared. The deduced amino acid
sequences and lengths of the ORFs were conserved
within each class but differed by 9 amino acids between
class I and class II strains (Figure 1).
Construction and characterization of an ompP4 mutant
We constructed and characterized an isogenic ompP4
mutant of H. ducreyi 35000HP, which was designated
35000HPompP4. PCR amplification of the ompP4 ORF
in 35000HPompP4 demonstrated the size shift from
859 bp to 1.7 kb expected by addition of the 840 bp kan
cassette (Figure 2A). In Southern blotting, the kan probe
did not bind to the 35000HP genome but did bind to an
8.6-kb DNA fragment of the mutant genome, as expected.
The ompP4 probe bound to a 7.8-kb DNA fragment of
the 35000HP genome and to an 8.6-kb fragment of the
35000HPompP4 genome (Figure 2B). Thus, the results
from the PCR and Southern blot analyses were consistent
with the insertion of a single antibiotic resistance cassette
in the appropriate locus for the 35000HPompP4 mutant.
Sarkosyl insoluble membrane fractions were prepared
from 35000HPompP4 and 35000HP. The fractions ob-
tained from 35000HPompP4 were similar to those of
35000HP, except for lack of expression of a 30 kDa band
(Figure 2C), the predicted size of OmpP4. These data
suggest that OmpP4 does sort to the outer membrane
[24]. 35000HPompP4 and 35000HP demonstrated similar
lipooligosaccharide (LOS) profiles as analyzed by SDS-
PAGE (data not shown). 35000HPompP4 and 35000HP
demonstrated identical growth rates in broth (data not
shown).
Role of OmpP4 in experimental human infection
Eight healthy adults (three males, five females; 5 Caucasian,
3 black; age range 21 to 56; mean age ± standard deviation,
31 ± 11 years) volunteered for the study. One subject with-
drew prior to inoculation. Two subjects (volunteers 313
and 314) were inoculated in the first iteration, two subjects
(volunteers 316 and 317) in the second iteration, and three
Figure 1 Identification of the ompP4 gene within H. ducreyi 35000HP. A, Map of the ompP4–containing locus. B, PCR amplification of the
ompP4 locus from genomic DNA of ten clinical isolates. Lanes 1–6, class I strains 35000HP, HD183, HD188, 82–029362, 6644, and 85–023233,
respectively; lanes 7–10, class II strains CIP542 TCC, DMC64, 33921 and HMC112, respectively; lane 11, negative control (no template added).
C, Alignment of four deduced OmpP4 sequences among 2 class I strains (35000HP and 82–029362) and 2 class II strains (DMC64 and CIP542).
Grey-highlighted residues are conserved within each class but differ between class I and class II strains. Shaded arrows denote the consensus
signal peptide cleavage and lipidation site.
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ation. An escalating dose–response study was used to
compare the virulence of the mutant and the parent. In
the first iteration, each subject was inoculated with a
fixed estimated delivered dose (EDD) (143 CFU) of
35000HP at three sites on one arm and varying EDDs
(51, 101 and 202 CFU) of 35000HPompP4 on the other
arm (Table 1). Pustules formed at 2 of 6 parent sites and
5 of 6 mutant sites. Because the mutant was able to
form pustules at doses similar to the parent, a second it-
eration using similar doses of parent and mutant was
performed per protocol: 2 volunteers were inoculated
with fixed EDD (128 CFU) of 35000HP on one arm and
varying EDD (60, 119 and 238 CFU) of 35000HPompP4on the other arm. Pustules formed at 5 of 6 parent sites
and 5 of 6 mutant sites (Table 1). After two iterations,
pustules formed at 7 of 12 parent sites and 10 of 12 mu-
tant sites, suggesting that the mutant could be more
virulent than the parent. As per protocol, an interim
analysis was performed in order to determine the num-
ber of sites that needed to be inoculated with the
mutant and the parent to have sufficient power to detect
a difference in the pustule formation rate should
35000HPompP4 be more virulent than 35000HP. In the
third iteration, 3 volunteers were inoculated with a par-
ent dose (75 CFU) comparable to that of the mutant
(116 CFU); pustules formed at 3 of 9 parent sites and at
1 of 9 mutant sites.
Figure 2 Mutagenesis of ompP4. A, Composite gel of the ompP4
locus amplified using primers that flank the ompP4 ORF. Lane 1,
standard; lane 2, 35000HPompP4; lane 3, 35000HP. B, Composite
Southern blot of 35000HPompP4 and 35000HP probed with the
cloned ompP4 insert (lanes 1, 2) or the kan cassette (lanes 3, 4).
Lanes 1 and 4, 35000HPompP4; lanes 2 and 3, 35000HP. C, SDS-PAGE
and Coomassie blue staining of OMPs prepared from 35000HPompP4
(lane 2) and 35000HP (lane 3); molecular markers are shown in lane 1,
with sizes indicated to the left of the panel. Arrow points to the 30 kDa
protein, the predicted size of OmpP4, missing in the ompP4 mutant.
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and the mutant was 100% at 21 sites each. Papules were
similar in size at mutant sites (mean, 20.4 mm2) as at par-
ent sites (mean, 27.6 mm2) 24 h after inoculation (P = 0.23).
The overall pustule formation rate was 52.4% (95% CI,
23.3%-81.5%) at 21 parent sites and 47.6% (95% CI, 21.7%-
73.5%) at 21 mutant sites (P = 0.74). Thus, the ompP4 mu-
tant was as virulent as the parent.
For the parent and mutant broth cultures used to pre-
pare the inocula, 108 of 108 parent colonies and 107 of
107 mutant colonies tested were phenotypically correct
(parent, kanamycin-sensitive; mutant, kanamycin-resistant).
H. ducreyi was recovered intermittently from surface
cultures of sites inoculated with the parent or mutant.
Of the 21 sites that were inoculated with the parent, 7
(33.3%) yielded at least one positive surface culture,
while 9 of 21 mutant sites (42.9%) yielded a positive sur-
face culture (P = 0.43). All colonies obtained from sur-
face cultures (n = 284 and n = 471) and biopsy specimens
(n = 72 and n = 144) from parent sites and mutant sites,
respectively, were phenotypically correct. Thus, all testedcolonies from the inocula, surface cultures and biopsy
specimens had the expected phenotype.
Biological activity of anti-OmpP4 antiserum
The abilities of H. ducreyi to resist phagocytosis and
complement-mediated bactericidal activity are key fea-
tures of the organism’s pathogenesis [10,25,26]. Although
the H. ducreyi ompP4 mutant was not attenuated for
pustule formation in the human challenge model,
immunization with OmpP4 could elicit protective anti-
bodies that enhance bactericidal or phagocytic activity,
as has been observed with NTHI e (P4). Therefore, we
recombinantly expressed OmpP4 and tested its ability
to generate biologically active antibodies in mice. Using
Western blot analysis, the polyclonal mouse antiserum
uniquely bound to purified recombinant OmpP4 and to
a 29.2 kDa membrane protein, the predicted molecular
weight of OmpP4, from whole cell lysates prepared from
35000HP (Figure 3).
We used this hyperimmune mouse serum (HMS)
raised against recombinant OmpP4 (HMS-P4) and com-
pared the percent survival of 35000HP in 10% HMS-P4.
As a positive control for bactericidal antibody activity
against H. ducreyi, we used hyperimmune pig serum
previously shown to enhance bactericidal activity (gift of
Thomas Kawula) [27]. As expected, the mean percent
survival of 35000HP decreased from 119.9% ± 41.4% in
normal pig serum to 53.1% ± 12.4% in hyperimmune pig
serum. In contrast, the mean percent survival of 35000HP
was 63.0% ± 6.9% in normal mouse serum (NMS) com-
pared with 93.4% ± 16.8% in HMS-P4. Thus, HMS-P4 did
not promote bactericidal killing of 35000HP.
We next investigated the ability of HMS-P4 to promote
phagocytosis of 35000HP by mouse monocyte-macrophage
J774A.1 cells using quantitative phagocytosis assays. After
opsonization with NMS, the mean percent phagocytosed
35000HP was 74.6% ± 11.5% compared to 86.3% ± 9.4% of
bacteria phagocytosed after opsonization with HMS-P4
(P = 0.13); thus, anti-OmpP4 antibodies did not enhance
phagocytosis of H. ducreyi.
Discussion
H. ducreyi expresses at least 11 genes encoding lipopro-
teins in vivo [13], only three of which have been charac-
terized for their roles in pathogenesis in humans [5,9,10].
For this study, we examined a previously uncharacterized
lipoprotein, OmpP4, which has homology to the H. influ-
enzae vaccine candidate e (P4). There are two phenotypic
classes of H. ducreyi strains, which express different
immunotypes and proteomes [28,29]. ompP4 transcripts
are expressed both in vitro and during human infection
[13], and ompP4 was conserved among all class I and class
II clinical isolates of H. ducreyi that were tested, although
there were minor differences in the deduced amino acid
Table 1 Response to inoculation of live H. ducreyi strains









Final outcome of sites
Papule Pustule Resolved
313 F 7 P 3 2 1 2
M 3 3 3
314 M 7 P 3 0 3
M 3 2 2 1
316 F 7 P 3 3 3
M 3 3 3
317 F 8 P 3 2 2 1
M 3 2 2 1
324 M 8 P 3 1 1 2
M 3 1 1 2
325 M 8 P 3 2 2 1
M 3 0 3
326 F 6 P 3 0 3
M 3 0 3
Volunteers 313 and 314 were inoculated in the first iteration. Volunteers 316 and 317 were inoculated in the second iteration. Volunteers 324, 325, and 326 were
inoculated in the third iteration. aF = female, M =male. bP = 35000HP, M = 35000HPompP4.
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sequenced. These data, coupled with the protein’s hom-
ology to e (P4), led us to hypothesize that OmpP4 may
play an essential role in the formation of pustules in the
human challenge model. However, 35000HPompP4
caused pustules to form at the same rate as the parent
strain, indicating that ompP4 is not necessary for viru-
lence in humans. Whether ompP4 contributes to viru-
lence for class II strains, which are not genetically
tractable, is unknown.
The experimental model of human infection closely
mimics natural infection, but it is limited to the papular
and pustular stages of disease. In natural disease, pus-
tules do not evolve into ulcers until several weeks after
initial infection. Thus, we cannot rule out a role for
OmpP4 during the ulcerative stage of disease. However,
during experimental infection, H. ducreyi remains extra-
cellular, where it associates with collagen, fibrin, poly-
morphonuclear leukocytes and macrophages. These
relationships are maintained in natural ulcers [5] and
thus it is unlikely that OmpP4 contributes to the ulcera-
tive stage.
One of the attractive characteristics of e (P4) as a vac-
cine candidate is its ability to generate bactericidal and/or
protective antibodies. We therefore examined whether
antibodies against OmpP4 could block the organism’s abil-
ity to resist either serum bactericidal activity or phagocyt-
osis. OmpP4-specific mouse antiserum had no effect on
H. ducreyi’s survival in serum bactericidal assays or on H.
ducreyi’s uptake by murine macrophages. It is possible
that important conformational epitopes of native OmpP4lipoprotein were not retained by the recombinant, non-
lipidated OmpP4 antigen used. However, similar manip-
ulations did not abrogate the ability of e (P4) to elicit
bactericidal antibodies. Overall, our data suggest that,
unlike NTHI e (P4), H. ducreyi OmpP4 is not a strong
vaccine candidate.
e (P4) is essential for heme uptake by NTHI under
aerobic conditions [15,16]. Like H. influenzae, H. ducreyi
is dependent upon uptake of iron in the context of a
porphyrin ring such as heme or hemoglobin for its sur-
vival. 35000HPompP4 and 35000HP had similar growth
rates under the heme-replete conditions used for the hu-
man challenge model, suggesting that ompP4 is not es-
sential for heme uptake. H. ducreyi also encodes three
TonB-dependent receptors, including hemoglobin recep-
tor HgbA, heme receptor TdhA, and the uncharacter-
ized TdX, for uptake of heme/iron. Among these three
receptors, only HgbA is required for virulence in the hu-
man model of chancroid, and HgbA alone is both neces-
sary and sufficient for heme/iron acquisition by H. ducreyi
[30,31]. Thus, H. ducreyi expresses several redundant
mechanisms for acquiring this essential nutrient, and any
contribution of OmpP4 to heme/iron uptake, like those of
TdhA or TdX, is likely secondary to the activity of HgbA.
H. influenzae e (P4) is necessary for utilization of the
essential coenzyme NAD + (V factor). Members of the
Pasteurellaceae cannot synthesize NAD + de novo and
must salvage either NAD + or a suitable nicotinamide-
based precursor from their environment [32]. So-called
V-factor dependent Pasteurellaceae can only utilize
NAD + or the precursors nicotinamide mononucleotide
Figure 3 Specificity of anti-OmpP4 antiserum. Western blot
probed with polyclonal antisera from mice inoculated with purified,
recombinant OmpP4. Lane 1, purified recombinant OmpP4; lane 2,
35000HP whole cell lysates. The predicted molecular weight of
recombinant, histidine-tagged OmpP4 is 29.2 kDa.
Janowicz et al. BMC Microbiology 2014, 14:166 Page 6 of 10
http://www.biomedcentral.com/1471-2180/14/166(NMN) or nicotinamide riboside (NR) [33,34]. This
NAD + salvage pathway is well characterized in H. influ-
enzae [32,34]: NAD+, NMN, and NR pass through por-
ins into the periplasm, where NAD + is converted to
NMN by the enzyme NadN, and NMN is converted to
NR primarily through the catalytic activity of e (P4)
[17,21,35]. The inner membrane transporter PnuC then
transports NR into the cytoplasm, where the enzyme
NadR converts NR to NAD + [36,37].
In contrast to H. influenzae, V-factor independent
Pasteurellaceae, such as H. ducreyi, can utilize the precur-
sor nicotinamide (NAm) to synthesize NAD + [34]. In
this alternative salvage pathway, NAm diffuses across
the cell wall into the cytoplasm, where the nicotinamide
phosphoribosyltransferase NadV converts NAm to NMN,
which is then converted to NAD+ by an unidentified
NMN adenylyltransferase [32,38]. Critical to this alterna-
tive salvage pathway is the enzyme NadV; in H. ducreyi
strains, the nadV gene is carried on extrachromosomal
or integrated copies of plasmid pNAD1, suggestinghorizontal transfer of nadV [38,39]. Strain 35000HP,
used to generate the ompP4 mutant, contains two tan-
dem, chromosomal copies of pNAD1 [39]. A previous
study reported that H. ducreyi 35000HP encodes a
complete H. influenzae-like NAD+ salvage pathway [37].
However, at that time the H. ducreyi genome and its an-
notation were only available in preliminary form. Our ana-
lysis of the finalized H. ducreyi 35000HP genome showed
that, while 35000HP includes full-length ORFs predicted
to encode intact homologs of e (P4) (ompP4) and the NR
transporter PnuC (HD1041), the homologs of nadN and
nadR are pseudogenes. H. influenzae NadR is a bifunc-
tional enzyme whose C-terminus contains NMN adenylyl-
transferase activity [37]. Possibly, the 3’ end of the H.
ducreyi nadR pseudogene may express a truncated NadR
with this activity. Alternatively, an as-yet-unidentified en-
zyme is required to convert NMN to NAD+ in H. ducreyi.
Overall, the absence of intact nadN and nadR genes
suggests that the H. influenzae-like NAD + salvage path-
way is dispensible in H. ducreyi because of NadV-driven
utilization of NAm. NadV activity most likely accounts
for our finding that 35000HPompP4 harbored no dis-
cernible growth defects. 35000HP is the only H. ducreyi
strain whose genome is available to date; thus, whether
OmpP4 activity is more critical for NAD + utilization in
other H. ducreyi strains, and whether other strains har-
bor a complete H. influenzae-like NAD + salvage path-
way, is unknown.Conclusions
The outer membrane protein OmpP4 is not required for
virulence of H. ducreyi in human disease. Antibodies
raised against the recombinant OmpP4 protein were not
able to enhance phagocytic uptake or serum bactericidal
activity, suggesting that OmpP4 would not be a suitable
candidate for an H. ducreyi vaccine. The known func-
tions of e (P4) in H. influenzae, including heme uptake
and NMN conversion to NR in the NAD utilization
pathway, are accomplished by different mechanisms in
H. ducreyi. A common theme in bacterial pathogenesis
is the redundancy of mechanisms used to accomplish
tasks critical for a pathogen’s survival. Thus, although e
(P4) plays an important role in H. influenzae pathogen-
esis, the activity of its homolog in H. ducreyi appears to
be redundant with the virulence factor HgbA and the
NadV-dependent NAD + salvage pathway.Methods
Bacteria and culture conditions
35000HP is a human-passaged variant of strain 35000
and has been reported previously [40]. H. ducreyi strains
were grown on chocolate agar plates supplemented with
1% IsoVitaleX at 33ºC in 5% CO2 or in GC base broth
Janowicz et al. BMC Microbiology 2014, 14:166 Page 7 of 10
http://www.biomedcentral.com/1471-2180/14/166culture supplemented with bovine hemin (50 mg/ml),
1% IsoVitaleX, and 5% fetal bovine serum.
Conservation of ompP4 in H. ducreyi clinical isolates
H. ducreyi strains have been categorized into one of two
different classes, based on their OMP profiles and LOS
migration patterns [5,28]. To examine whether ompP4
was conserved among strains of both classes, we isolated
genomic DNA from the following six class I strains:
35000HP (Winnipeg), HD183 (Singapore), HD188 (Kenya),
82–029362 (California), 6644 (Boston), and 85–023233
(New York). Genomic DNA was also isolated from the
following four class II strains: CIP542 ATCC (Hanoi),
HMC112 (CDC), 33921 (Kenya), DMC64 (Bangladesh).
The ompP4 ORF was PCR amplified, using primers 5’-
GCGATATTAAGTGGCAACTAGCGG-3’ and 5’-GCA
AATTAACCTCTCCCAACAGCCTG-3’ that were ex-
ternal to the ORF, from genomic DNAs isolated from
the above strains. Amplicons from two class I and two
class II strains were sequenced and compared.
Construction and characterization of an ompP4 mutant of
strain 35000HP
An 840 bp kan cassette that consists almost entirely of
aphA-3 coding sequence from pUC18K3 [41] was ligated
into a 3.9 kb ompP4-encoding region of the 35000HP gen-
ome that had been cloned into the pBluescript plasmid.
Because ompP4 lies within a putative operon (Figure 1), a
non-polar kan cassette was used, in which the 840 bp se-
lectable kanamycin resistance gene (aphA-3) is immedi-
ately followed by a consensus ribosomal-binding site and
a start codon [41].
Sequence analysis of one resulting plasmid confirmed
that the kan cassette was inserted 187 bp downstream
from the transcriptional start of the 831-bp ompP4 ORF.
A 4.7-kb EcoRI/XhoI fragment of this plasmid was sub-
cloned into pRSM2072, which utilizes lacZ as a counter-
selectable marker to facilitate allelic exchange [42]. The
resulting plasmid was electroporated into strain 35000HP.
Selection was performed on plates containing kanamycin
(30 μg/mL). Colonies were then picked and grown on
plates containing X-Gal (5-bromo-4-chloro-3-indoyl-β-D-
galactopyranoside) and kanamycin. Cointegrates appeared
as small blue colonies because the growth of 35000HP
containing lacZ is suppressed in the presence of X-Gal
[42]. lacZ-deficient colonies in which a second cross-
over event had occurred appeared as white, larger col-
onies. An ompP4 mutant was recovered and designated
35000HPompP4.
Construction of the mutant was confirmed using PCR
amplification and Southern blotting. PCR amplification
of the ompP4 ORFs of 35000HPompP4 and 35000HP
was performed using primers (5’-TGTACTTATCATCA-
TAATCATAAGCAT-3’ and 5’-TTTGTTAGGATTAACTCGTTATTCA-3’) specific to the intergenic regions
flanking ompP4, followed by agarose gel electrophoresis.
For Southern blot analysis, H. ducreyi DNA was digested
to completion with PstI, electrophoresed on 0.8% agarose
gels and probed with either the cloned ompP4 insert or
the kan cassette.
LOS and OMPs were purified from 35000HP and
35000HPompP4 and analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, as described [9]. The
growth rates of parent and mutant in broth used to pre-
pare the challenge inocula were also compared.
Human inoculation protocol
Stocks of 35000HP and 35000HPompP4 were prepared
according to the US Food and Drug Administration
guidelines (BB-IND 13046). For the human inoculation
protocol, healthy adult male and female volunteers over
21 years of age were recruited for the study. Subjects
gave informed consent for participation and for human
immunodeficiency virus (HIV) serology, in accordance
with the human experimentation guidelines of the U.S.
Department of Health and Human Services and the insti-
tutional ethics committee of Indiana University-Purdue
University of Indianapolis. The experimental protocol,
preparation and inoculation of the bacteria, calculation of
the EDD, and clinical observations were all done exactly
as described previously [12,43]. Subjects were observed
until they reached clinical endpoint, which was defined as
resolution of all sites, development of a pustule that was
either painful or > 4 mm in diameter, or 14 days after in-
oculation. Subjects were then treated with one dose of oral
ciprofloxacin as described [44].
Comparison of papule and pustule formation rates for
the two strains was performed using a logistic regression
model with generalized estimating equations (GEE) to
account for the correlation among sites within the same
individual, as previously described [43]. The GEE sand-
wich estimate for the standard errors was used to calcu-
late 95% confidence intervals (95% CI) for these rates.
To confirm that the inocula contained or lacked the
kan cassette and that the kan cassette was not lost by
the mutant during the course of infection, individual
colonies from the inocula, surface cultures and biopsy
specimens were picked, suspended in freezing medium
and frozen in 96-well plates. If available, thirty colonies
from an individual specimen were scored for susceptibility
to kanamycin on kanamycin-containing chocolate agar
plates as described [31].
Recombinant fusion protein construction and expression
The ompP4 ORF, without the signal peptide sequence,
was amplified from 35000HP genomic DNA using syn-
thetic primers (5’-TGTACTTATCATCATAATCATAAG-
CAT-3’ and 5’-TGAATAACGAGTTAATCCTAACAAA
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using the TOPO XL Cloning Kit (Invitrogen Corp, San
Diego, Calif ). The fragment was excised using EcoRI and
then cloned into pRSETB (Invitrogen). Transformation of
recombinant plasmid into BL21(DE3)pLysS cells allowed
for fusion protein expression. Recombinant OmpP4 was
expressed in inclusion bodies and was purified under con-
ditions using urea following the QIAexpressionist System
(Qiagen, Inc, Valencia, Calif). Stepwise dialysis with de-
creasing urea concentrations was used to remove urea
from the recombinant proteins and then concentrated
with a Centricon-10 microconcentrator (Amicon Corp.,
Beverly, Mass). Purified recombinant OmpP4 was used to
inoculate BALB/c mice to produce polyclonal antibodies
(Harlan Bioproducts for Science) that were used in bac-
tericidal and phagocytosis assays.Immune serum bactericidal assays
35000HP was grown for 16–18 h from a freezer stock
on chocolate agar plates at 33°C with 5% CO2 and har-
vested in phosphate-buffered saline. After vortexing for
30 sec, cells were suspended in GC medium and diluted
to a final concentration of approximately 103 to
104 CFU/ml. Bactericidal assays were performed in 96-
well plates. Each well received 50 μl 35000HP and 10 μl
(or 10%) of heat-inactivated NMS or HMS-P4 and
brought to 65 μl with GC broth. Plates were incubated
for 30 min at 33°C with 5% CO2. Then, 25 μl of either
active or heat-inactivated normal human serum, which
was used as the complement source, was added and the
plates were incubated for an additional 60 min at 33°C
with 5% CO2. Bacteria were quantified by plating 100 μl
from each well onto chocolate agar and incubating for
48 h at 33°C with 5% CO2. Heat-inactivated hyper-
immune pig serum collected after multiple inoculations
with H. ducreyi, which has been shown to promote bac-
tericidal activity against H. ducreyi, was used as a posi-
tive control (kindly provided by Thomas Kawula,
University of North Carolina, Chapel Hill) [27]. Data
were reported as percent survival in active NHS compared
to that in heat-inactivated-NHS. Each experiment was re-
peated three times, and arithmetic mean and standard de-
viation of the percent survival were calculated.Phagocytosis assays
The mouse monocyte-macrophage cell line J774A.1
(TIB-67; American Type Culture Collection) was cul-
tured in Dulbecco's modified Eagle's medium (DMEM;
BioWhittaker) supplemented with 4 mM GlutaMAX,
10% (vol/vol) heat-inactivated fetal bovine serum (FBS),
and 1 mM sodium pyruvate. The cells, which were kept
in culture for less than 1 month, were used only at low
passage numbers. Twenty hours before infection, thecells were allowed to adhere to coverslips in 24-well tis-
sue culture plates (2 × 105 cells/well). The following day,
nonadherent cells were removed by washing twice with
RPMI-F. 35000HP containing the green fluorescent
protein-expressing plasmid pRB157K (courtesy of R. J.
Blick and E. J. Hansen) was grown to mid-logarithmic
phase in Columbia broth without FBS and with strepto-
mycin (100 μg/ml) and then centrifuged at 6,500 × g for
10 min. 35000HP(pRB157K) was suspended to an OD660
of 0.2, yielding approximately 107 CFU/ml. A 900 μl por-
tion of bacteria was opsonized with 100 μl of either
NMS or HMS-P4 and incubated for 30 min at RT. The
suspensions were subjected to centrifugation, and the
resulting pellets were suspended in 900 μl of RPMI-F.
Approximately 2 × 106 CFU of opsonized bacteria were
added to wells containing J774A.1 cells (2 × 105 cells)
for a multiplicity of infection of 10:1. Samples were cen-
trifuged at 150 x g for 2 minutes, and phagocytosis was
allowed to proceed at 37°C for 40 min. Phagocytosis was
stopped by placing the tissue culture plate on ice. Cells
were then fixed with 3.7% paraformaldehyde in PBS.
Phagocytosis was evaluated by confocal microscopy, as
described previously [43]. Briefly, after washing in DMEM-
FBS, samples were stained with affinity-purified rat anti-
mouse CD45 monoclonal antibody (R&D Systems, Minne-
apolis, MN) followed by DyLight Fluor 649-conjugated
goat anti-rat secondary antibody (Jackson ImmunoRe-
search Laboratories, West Grove, Pa.). Nuclei were visual-
ized with Hoechst 33342. Samples were mounted onto
slides with Vectashield mounting medium (Vector Labora-
tories) and examined under an Olympus FV1000-MPE
confocal laser-scanning microscope. To assess whether
bacteria were phagocytosed or remained extracellular, arbi-
trary fields in each sample were optically sectioned in
0.2 μm steps. The optical sections were stacked and ani-
mated using ImageJ software (Rasband, W.S., ImageJ, U. S.
National Institutes of Health, Bethesda, Maryland, USA) to
allow for examination of the relative positions of the bac-
teria and eukaryotic cells in three dimensions. Numbers of
intracellular and extracellular bacteria were recorded to de-
termine percent of bacteria phagocytosed, which was cal-
culated as: (total number of intracellular bacteria/total
number of bacteria) x 100. Three independent experiments
were performed and the mean percent phagocytosed bac-
teria was calculated and compared between bacteria op-
sonized with NMS and bacteria opsonized with HMS-P4.
Statistical analysis was performed using paired Student’s t
tests.Abbreviations
EDD: Estimated delivered dose; HMS-P4: Hyperimmune mouse serum raised
against recombinant H. ducreyi OmpP4; kan cassette: Nonpolar mutagenic
cassette encoding kanamycin resistance gene; LOS: Lipooligosaccharide;
NMS: Normal mouse serum; NTHI: Nontypeable Haemophilus influenzae;
OMP(s): Outer membrane protein(s); ORF: Open reading frame.
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